Hepatitis vaccines are essential tools in preventing viral infections that target the liver, specifically Hepatitis A and Hepatitis B. The Hepatitis A vaccine is vital for safeguarding against contamination-related infections, commonly transmitted through contaminated food or water. It is particularly recommended for travelers to regions with a higher prevalence of Hepatitis A. The Hepatitis B vaccine is a key component in preventing chronic Hepatitis B infections, which can lead to severe liver diseases, including cirrhosis and liver cancer. Administered as part of routine childhood immunization schedules, it is also recommended for adults, especially those at an increased risk of exposure. Combined vaccines, such as the Hepatitis A and B combination, provide comprehensive protection against both viruses. Beyond individual protection, widespread vaccination efforts contribute significantly to public health by reducing the overall burden of Hepatitis-related diseases globally. Continuous research and development efforts aim to expand vaccine coverage, addressing additional Hepatitis strains and reinforcing the commitment to preventing and controlling Hepatitis infections on a global scale. Regular vaccination campaigns and healthcare initiatives remain critical in promoting broad immunization against Hepatitis.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria